BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026)
BridgeBio Pharma (BBIO) posted FCF Margin of 101.46% for Q1 2026, down 172.02% sequentially from 37.3% in Q4 2025, and up 6937.0% YoY from 1.44% in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026) Analysis & Trends
BridgeBio Pharma has reported FCF Margin for 8 years, with the latest figure at 101.46% in Q1 2026.
- Quarterly FCF Margin rose 6937.0% year-over-year to 101.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.75% (up 31567.0% YoY) and the FY2025 annual result came in at 89.03%, up 14576.0% from the prior year.
- FCF Margin slipped to 101.46% in Q1 2026 per BBIO's latest filing, from 37.3% in the prior quarter.
- Over five years, FCF Margin peaked at 3474.54% in Q2 2024 and troughed at 39042.01% in Q3 2022.
- A 5-year average of 5083.8% and a median of 3320.83% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 3393271 bps in 2022, then jumped 3549818 bps in 2023.
- Over 5 years, FCF Margin stood at 5240.86% in 2022, then slumped by 36 bps to 7147.68% in 2023, then soared by 54 bps to 3320.83% in 2024, then jumped by 99 bps to 37.3% in 2025, then plunged by 172 bps to 101.46% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 101.46%, 37.3%, and 90.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -29.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.36% |
| Mar 31, 2026 | -101.46% |
| Dec 31, 2025 | -36.62% |
| Sep 30, 2025 | -91.17% |
| Jun 30, 2025 | -73.20% |
| Mar 31, 2025 | -171.11% |
| Dec 31, 2024 | -3,321.54% |
| Sep 30, 2024 | -6,614.31% |
| Jun 30, 2024 | 3,443.22% |
| Mar 31, 2024 | -104.32% |
| Dec 31, 2023 | -7,177.88% |
| Sep 30, 2023 | -3,560.43% |
| Jun 30, 2023 | -6,928.52% |
| Mar 31, 2023 | -7,908.98% |
| Dec 31, 2022 | -5,029.09% |
| Sep 30, 2022 | -40,213.61% |
| Jun 30, 2022 | -44.55% |
| Mar 31, 2022 | -9,533.29% |
| Dec 31, 2021 | -1,364.31% |
| Sep 30, 2021 | -5,461.73% |